These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 33682388)

  • 1. [SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice].
    Scheen AJ; Delanaye P
    Rev Med Liege; 2021 Mar; 76(3):186-194. PubMed ID: 33682388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SGLT2 inhibitors, new option to prevent or treat heart failure].
    Scheen AJ; Lancellotti P
    Rev Med Liege; 2021 Apr; 76(4):248-255. PubMed ID: 33830688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.
    Czupryniak L; Mosenzon O; Rychlík I; Clodi M; Ebrahimi F; Janez A; Kempler P; Małecki M; Moshkovich E; Prázný M; Sourij H; Tankova T; Timar B
    Diabetes Obes Metab; 2024 Oct; 26(10):4165-4177. PubMed ID: 39140231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Diabetes; 2021 Jan; 70(1):1-16. PubMed ID: 33106255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
    [No Abstract]   [Full Text] [Related]  

  • 8. [EMPA-KIDNEY: empagliflozin in chronic kidney disease].
    Delanaye P; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):24-28. PubMed ID: 36634063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
    Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DAPA-CKD: Significant Victory for CKD with or without Diabetes.
    Patel AB; Mistry K; Verma A
    Trends Endocrinol Metab; 2021 Jun; 32(6):335-337. PubMed ID: 33676827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis.
    Shiau CH; Tsau LY; Kao CC; Peng YC; Bai CH; Wu JC; Hou WH
    Int Urol Nephrol; 2024 Apr; 56(4):1359-1381. PubMed ID: 37752340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease.
    Scheen AJ
    Clin Pharmacokinet; 2020 Aug; 59(8):981-994. PubMed ID: 32201911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
    Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
    Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Bakis H; Pfirmann P; Combe C; Rigothier C
    Nephrol Ther; 2022 Dec; 18(6S1):6S17-6S24. PubMed ID: 36585121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.